May 2nd 2024
Phase 3b data support venetoclax as a treatment option in CLL for patients with or without B-cell receptor–associated kinase inhibitor treatment.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden
December 19th 2023Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.
Acalabrutinib Regimen Yields Significant PFS Improvements in Untreated CLL
December 12th 2023Acalabrutinib on its own or in combination with obinutuzumab increases PFS and ORR in patients with chronic lymphocytic leukemia regardless of mutation status, according to follow-up data from the ELEVATE-TN trial.
Ibrutinib/Venetoclax Combo Shows PFS, OS Benefit as MRD-Guided Regimen in Frontline CLL
December 10th 2023When used as a minimal residual disease (MRD)–guided treatment approach, ibrutinib (Imbruvica) combined with venetoclax (Venclexta) improved progression-free and overall survival (OS) compared with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive chronic lymphocytic leukemia (CLL), as observed in the phase 3 FLAIR trial.
Zanubrutinib Improves PFS Vs Ibrutinib in Relapsed or Refractory CLL/SLL
December 10th 2023Treatment with zanubrutinib also appears to improve overall survival compared with ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 3 ALPINE trial.